Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
Today, 12:28 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABMD

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

FDA Approves Zoetis’ Solensia To Control Osteoarthritis Pain In Cats

By Vandana Singh
Today, 12:28 PM
The 

ZTS

Read More
3 minute read
  • FDA
  • News

Zoetis Announces FDA Approval of Simparica Trio New Label Indication For Prevention Of Borrelia Burgdorferi Infections In Dogs

By Benzinga Newsdesk
Today, 12:28 PM
ARSIPPANY, N.J. –January 4, 2022– Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio® (sarolaner, moxidectin, and

ZTS

Read More
1 minute read
  • Media
  • Trading Ideas

Trader Stephanie Link Says She Sold Zoetis, Bought J&J

By Benzinga Newsdesk
Today, 12:28 PM
-CNBC's "Fast Money: Halftime Report"

JNJ

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Citigroup Maintains Neutral on Zoetis, Raises Price Target to $232

By Benzinga Newsdesk
Today, 12:28 PM
Citigroup analyst Navann Ty maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $184 to $232.

ZTS

Read More
1 minute read
  • Buybacks
  • Dividends
  • General
  • Health Care
  • News

Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of $3.5B

By Vandana Singh
Today, 12:28 PM
The board of directors of Zoetis Inc (NYSE:ZTS) has approved a $3.5 billion share repurchase program. The company added that the…

ZTS

Read More
10 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For November 18, 2021

By Benzinga Insights
Today, 12:28 PM
Upgrades

APP

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Barclays Maintains Overweight on Zoetis, Raises Price Target to $240

By Benzinga Newsdesk
Today, 12:28 PM
Barclays maintains Zoetis (NYSE:ZTS) with a Overweight and raises the price target from $235 to $240.

ZTS

Read More
32 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For November 4, 2021

By Benzinga Insights
Today, 12:28 PM
  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

Read More
1 minute read
  • Media
  • Small Cap

Cramer Weighs In On Lennar, Alibaba And More

By Craig Jones
Today, 12:28 PM
On CNBC's "Mad Money Lightning Round," Jim Cramer said he needs something less speculative than Original BARK Co (NYSE: BARK).

BABA

Posts navigation

Previous 1 … 4 5 6 … 10 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service